Aastrom has estimated their gross revenue to reach up to 13.5$ million with a recent offering with BMO Capital Markets, Corp. This agreement is for a registered direct offering of 11,842,105 shares of Aastrom's common stock and warrants to purchase up to 5,921,053 shares of Aastrom's common stock for certain institutional investors. Under the agreement, shares of common shares and warrants will be sold in the form of units which consist of one share of common stock and warrants to purchase 0.5 shares of common stock. This is priced at $1.14 per unit.
The full article can read at http://www.beaconequityresearch.com
About Aastrom Biosciences, Inc. (NASDAQ: ASTM)
Aastrom Biosciences, Inc. was founded in 1989 and has its headquarters in Ann Arbor Michigan. It is a regenerative medicine company which focuses on the clinical development of autologous cell products for the repair or regeneration of multiple human tissues based on its proprietary Tissue Repair Cell (TRC) technology. This technology is based on its cell products, which are a unique cell mixture containing large numbers of stem and progenitor cells, produced outside of the body from a small amount of bone marrow taken from the patient, and the means to produce these products in an automated process. For more information, you may visit the company’s website at: http://www.aastrom.com
